SYRS News and Press, Syros Pharmaceuticals Inc. From 05/22/20

Investing in companies with superior growth rates can produce outstanding returns over the long term. A stock is essentially a share in the ownership of a business, and the price of the stock will follow the value of the business over time. When the business is growing rapidly and ideally ac...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor,...

Syros Pharmaceuticals, Inc. (SYRS) Q1 2020 Earnings Conference Call May 07, 2020, 08:30 ET Company Participants Naomi Aoki - VP, Corporate Communications & IR Nancy Simonian - President, CEO & Director Joseph Ferra - CFO David Roth - Chief Medical Officer Conference ...

Image source: The Motley Fool. Syros Pharmaceuticals, Inc.   (NASDAQ: SYRS) Q1 2020 Earnings Call May 07, 2020 , 8:30 a.m. ET Operator Continue reading

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.39 beats by $0.03 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Completed Enrollment in Phase 2 Trial Cohort Evaluating SY-1425 in RARA-Positive Relapsed or Refractory AML Patients On Track for 2020 Milestones, Including Clinical Data Readouts for SY-1425 and SY-5609 Well-Funded with Cash Runway into 2022 Management to Host Conference Ca...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a co...

Introduction Syros ( SYRS ) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RARα ago...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results...